HWHans Wallberg

Hans Wallberg

*This is an algorithmically generated author record based on publicly available information.

Hans Wallberg has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Data1 from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma

    by Hong Jae Chon, Jeong Heo, Do Young Kim, Ho Yeong Lim, Teresa Macarulla, Carlos Gomez Martín, Victor Moreno, Maria Reig, Min-Hee Ryu, Jung-Hwan Yoon, et al.

    Contents: Figure S1. Longitudinal measure of ALT, AST,total bilirubin levels, and ALBI score. Figure S2. Longitudinal measure of neutrophil levels and thrombocyte levels Figure S3. Dose reduction and discontinuation due to adverse events Figure S4. Pharmacokinetics; plasma concentrations for fostrox and troxacitabine Figure S5. Liver biopsy PD marker expression Table S1. Exposure to fostrox and troxacitabine in plasma after one cycle of fostrox administration Table S2. Representativeness of Study Participants

  • Open Access

    Data from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma

    by Hong Jae Chon, Jeong Heo, Do Young Kim, Ho Yeong Lim, Teresa Macarulla, Carlos Gomez Martín, Victor Moreno, Maria Reig, Min-Hee Ryu, Jung-Hwan Yoon, et al.

    Purpose:Immunotherapy has significantly improved outcomes in advanced hepatocellular carcinoma (HCC). However, most patients eventually progress, and second-line (2L) options remain limited. Fostroxacitabine bralpamide (fostrox), a liver-targeted prodrug, was administered in combination with lenvatinib, aiming at enhancing antitumor activity while avoiding further deterioration of residual liver function. Patients and Methods:This multicenter, single-arm phase Ib/IIa study evaluated the safety, pharmacokinetics (PK)/pharmacodynamics, and efficacy of fostrox (orally for 5 days in 21-day cycles), plus lenvatinib (standard doses), in locally advanced unresectable or metastatic HCC progressed on first-line/2L therapy (NCT03781934). A 3 + 3 dose-escalation design was used to determine the recommended phase II dose (RP2D). Results:Twenty-one patients were enrolled, and the median follow-up was 10.5 months. No dose-limiting toxicities were observed, and the RP2D of fostrox was established at 30 mg. All patients reported adverse events (AE), with 81% being grade ≥3 with possible relation to fostrox in 52.5% and to lenvatinib in 66.7% of cases. Fostrox-related AEs were mainly transient neutropenia and thrombocytopenia. Other AEs, mainly attributed to lenvatinib, were grade I/II and consistent with monotherapy use. Fostrox dose reduction and discontinuation rates were 29% and 5%, and for lenvatinib the rates were 52% and 14%, respectively. There were no signs of treatment-related liver function deterioration. The overall response rate was 24%, disease control rate was 81%, median time to progression was 10.9 months, median progression-free survival was 6.7 months, and median overall survival was 13.7 months. Fostrox PK analyses confirmed dose proportionality, and liver biopsies showed tumor-selective DNA damage. Conclusions:The combination of fostrox and lenvatinib demonstrated promising preliminary efficacy and tolerability after immunotherapy, supporting further investigation as a 2L option in advanced HCC.

  • Open Access

    A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma

    by Hong Jae Chon, Jeong Heo, Do Young Kim, Ho Yeong Lim, Teresa Macarulla, Carlos Gomez Martín, Victor Moreno, Maria Reig, Min-Hee Ryu, Jung-Hwan Yoon, et al.

    Purpose: Immunotherapy has significantly improved outcomes in advanced hepatocellular carcinoma (HCC). However, most patients eventually progress, and second-line (2L) options remain limited. Fostroxacitabine bralpamide (fostrox), a liver-targeted prodrug, was administered in combination with lenvatinib, aiming at enhancing antitumor activity while avoiding further deterioration of residual liver function. Patients and Methods: This multicenter, single-arm phase Ib/IIa study evaluated the safety, pharmacokinetics (PK)/pharmacodynamics, and efficacy of fostrox (orally for 5 days in 21-day cycles), plus lenvatinib (standard doses), in locally advanced unresectable or metastatic HCC progressed on first-line/2L therapy (NCT03781934). A 3 + 3 dose-escalation design was used to determine the recommended phase II dose (RP2D). Results: Twenty-one patients were enrolled, and the median follow-up was 10.5 months. No dose-limiting toxicities were observed, and the RP2D of fostrox was established at 30 mg. All patients reported adverse events (AE), with 81% being grade ≥3 with possible relation to fostrox in 52.5% and to lenvatinib in 66.7% of cases. Fostrox-related AEs were mainly transient neutropenia and thrombocytopenia. Other AEs, mainly attributed to lenvatinib, were grade I/II and consistent with monotherapy use. Fostrox dose reduction and discontinuation rates were 29% and 5%, and for lenvatinib the rates were 52% and 14%, respectively. There were no signs of treatment-related liver function deterioration. The overall response rate was 24%, disease control rate was 81%, median time to progression was 10.9 months, median progression-free survival was 6.7 months, and median overall survival was 13.7 months. Fostrox PK analyses confirmed dose proportionality, and liver biopsies showed tumor-selective DNA damage. Conclusions: The combination of fostrox and lenvatinib demonstrated promising preliminary efficacy and tolerability after immunotherapy, supporting further investigation as a 2L option in advanced HCC.

  • Open Access

    A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases

    by Ruth Plummer, Alastair Greystoke, Gregory Naylor, Debashis Sarker, Anm Kaiser Anam, Hans Prenen, Laure-Anne Teuwen, Eric Van Cutsem, Jeroen Dekervel, Beate Haugk, et al.

    Purpose: To evaluate safety, preliminary efficacy, pharmacokinetics, and pharmacodynamics, of fostroxacitabine bralpamide (fostrox, MIV-818), a novel oral troxacitabine nucleotide prodrug designed to direct exposure to the liver, while minimizing systemic toxicity. Patients and Methods: Fostrox monotherapy was administered in an open-label, single-arm, first-in-human, phase 1a/1b study, in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, or solid tumor liver metastases. The first part (1a) consisted of intra/inter-patient escalating doses (3 mg to 70 mg) QD for up to 5 days, and the second part (1b), doses of 40 mg QD for 5 days, in 21-day cycles. Safety and tolerability were evaluated by the Safety Review Committee, and efficacy was assessed every 6 weeks with CT or MRI using RECIST 1.1 and mRECIST. Results: Nineteen patients were treated with fostrox. Most common adverse events (AEs) were hematological and increased AST. Grade 3 treatment related AEs (TRAE) were seen in 53% of the patients, with transient neutropenia and thrombocytopenia as the most common. No grade 5 AE was observed. Recommended Phase 2 dose of fostrox was 40 mg QD for 5 days in 21-day cycles. Preliminary efficacy showed a clinical benefit rate in the liver of 53% and stable disease (SD) as best response in 10 patients. Liver targeting with fostrox was confirmed with higher exposure of troxacitabine and its metabolites in liver compared to plasma. Systemic exposure of fostrox was generally low with troxacitabine as main analyte. Biopsies demonstrated tumor-selective, drug-induced DNA damage. Conclusion: The phase 1a/1b monotherapy study of fostrox, in patients with liver tumors, showed a tumor selective effect in the liver and that 40 mg QD for 5 days in 21-day cycles is safe and tolerable. Safety and preliminary efficacy in patients with advanced HCC supports clinical development of fostrox in combination with other modes of action in HCC.